“…GST inhibitors are emerging as promising therapeautic agents for managing the development of resistance amongst anticancer agents. For this aim, various compound groups have been determined targeting this system as GST inhibitors and investigated its effects experimentally and clinically 17,18 . These groups are combined with ethacrynic acid and its derivatives, glutathione analogues, plant polyphenolic compounds, bifunctional inhibitors, antimalarial drugs, tocopherols, haloenol lactones, 7-nitro-2,1,3-benzoksadiazole derivatives, and prodrugs activated by GST such as, TLK 286, purine analogues, and nitric oxide donors 1 .…”